Mr. Mikhail Blagosklonny is an undisputed scientist and a professor of oncology who currently works at RPCI (Roswell Park Cancer Institute). He earned both his master degree in internal medicine and Ph.D. in cardiology and experimental medicine from First Pavlov State Medical University. Before joining Roswell Park Cancer Institute, Mikhail was an associate professor at the New York Medical College. Furthermore, Mikhail worked as a scientist at the Ordway Research Institute, where most of his research were focusing on cancer treatment, anti-aging drugs, aging mechanism, and cancer therapies. Perhaps, Blagosklonny is a passionate advocate of the cancer drug known as Rapamycin. He even developed a hypothesis on the role of TOR signaling in aging and cancer treatment. According to the hypothesis, Rapamycin drug can prolong the life of a human being.
Mikhail Blagosklonny serves as a chief editor to several publications such as Cell Cycle and Oncotarget. He also works as an associate editor of the editorial board of Cancer Therapy and Biology. He understands that it is not a miracle to have a society that is free from aging and cancer effects. Because of this reason, Mikhail has dedicated most of his time in conducting more research in oncology study. In addition to his hypothesis, Blagosklonny zeroes in cellular biology, molecular biology, tumor suppressors, clinical investigation, ontogenesis, and anti-cancer therapeutics. Also, Mikhail has made a lot of contributions to the science journals. He believes that through journals, people can be aware of the things that are happening in their life. Mr. Mikhail Blagosklonny has written more than 300 articles. Most of his publications are about cell cyclotherapy, aging hyperfunction, and chemotherapeutic engineering.
Visit ResearchGate.Net to know more about Mikhail’s latest work.